This article was originally published in The Gray Sheet
Executive SummaryPatient enrollment begins for a 400-eye, Phase III study to be used to support an eventual premarket approval application submission for its Refractec corneal shaping system that uses radiofrequency energy. Potential applications for the $40,000 device include low hyperopia, presbyopia and overcorrections by excimer laser treatment. Data released March 15 from a 65-eye Phase II study of the device in hyperopic patients shows the non-laser system achieved uncorrected visual acuity of 20/40 or better for the entire cohort 12 months post-operatively. All treated eyes had best corrected visual acuity of 20/25 or better, the Laguna Hills, California firm says. Patients treated in the study had +1 to +4.5 diopters of hyperopia, and 100% were within 1 diopter of the attempted correction at 12 months
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.